DGX insider buying and SEC filings, explained
Quest Diagnostics Inc. · CIK 1022079
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$778K
Planned sales (10b5-1)
$36.5M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 26, 2026 | Planned (10b5-1) | Gary M. Pfeiffer (Director) sold 1,203 shares at $243.00 ($292K), marked as a 10b5-1 plan trade. Holdings down 4% to 29,802 shares. | SEC filing Filed Oct 28, 2026, 6:05 PM ET |
| Sep 1, 2026 | Planned (10b5-1) | J. E. Davis (CEO and Director) sold 10,000 shares at $242.72 ($2.4M), marked as a 10b5-1 plan trade. Holdings down 8% to 122,423 shares. | SEC filing Filed Sep 3, 2026 |
| Aug 28, 2026 | Planned (10b5-1) | Michael E. Prevoznik (SVP & General Counsel) sold 22,677 shares at about $243.12 ($5.5M), marked as a 10b5-1 plan trade. Holdings down 38% to 37,557 shares. | SEC filing Filed Aug 31, 2026 |
| Jul 28, 2026 | Planned (10b5-1) | Mark E. Delaney (SVP & Chief Commercial Officer) sold 1,600 shares at $235.18 ($376K), marked as a 10b5-1 plan trade. Holdings down 13% to 10,335 shares. | SEC filing Filed Jul 29, 2026 |
| Jun 4, 2026 | Planned (10b5-1) | Karthik Kuppusamy (SVP, Clinical Solutions) sold 8,147 shares at $200.00 ($1.6M), marked as a 10b5-1 plan trade. Holdings down 38% to 13,510 shares. | SEC filing Filed Jun 8, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | J. E. Davis (CEO and Director) sold 10,000 shares at $194.14 ($1.9M), marked as a 10b5-1 plan trade. Holdings down 7% to 132,423 shares. | SEC filing Filed Jun 2, 2026 |
| Mar 5, 2026 | Planned (10b5-1) | Catherine T. Doherty (EVP, Regional Businesses) sold 5,558 shares at $206.21 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 8% to 67,122 shares. | SEC filing Filed Mar 6, 2026 |
| Mar 5, 2026 | Planned (10b5-1) | Michael E. Prevoznik (SVP & General Counsel) sold 3,878 shares at $206.21 ($800K), marked as a 10b5-1 plan trade. Holdings down 9% to 37,557 shares. | SEC filing Filed Mar 6, 2026 |
| Mar 5, 2026 | Planned (10b5-1) | Patrick Plewman (SVP for Diagnostic Services) sold 2,855 shares at $206.21 ($589K), marked as a 10b5-1 plan trade. Holdings down 16% to 15,198 shares. | SEC filing Filed Mar 6, 2026 |
| Mar 4, 2026 | Sale | Karthik Kuppusamy (SVP, Clinical Solutions) sold 2,628 shares at $204.86 ($538K). Holdings down 16% to 13,441 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 6, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Catherine T. Doherty (EVP, Regional Businesses) sold 632 shares at $207.73 ($131K), marked as a 10b5-1 plan trade. Holdings down 1% to 67,122 shares. | SEC filing Filed Mar 4, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Michael E. Prevoznik (SVP & General Counsel) sold 526 shares at $207.73 ($109K), marked as a 10b5-1 plan trade. Holdings down 1% to 37,557 shares. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | J. E. Davis (CEO and Director) sold 10,000 shares at $212.52 ($2.1M), marked as a 10b5-1 plan trade. Holdings down 8% to 117,185 shares. | SEC filing Filed Mar 4, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Patrick Plewman (SVP for Diagnostic Services) sold 410 shares at $207.73 ($85K), marked as a 10b5-1 plan trade. Holdings down 3% to 15,198 shares. | SEC filing Filed Mar 4, 2026 |
| Feb 19, 2026 | Planned (10b5-1) | Catherine T. Doherty (EVP, Regional Businesses) sold 1,433 shares at $204.83 ($294K), marked as a 10b5-1 plan trade. Holdings down 2% to 68,402 shares. | SEC filing Filed Feb 20, 2026 |
| Feb 19, 2026 | Planned (10b5-1) | Patrick Plewman (SVP for Diagnostic Services) sold 958 shares at $204.83 ($196K), marked as a 10b5-1 plan trade. Holdings down 6% to 15,838 shares. | SEC filing Filed Feb 20, 2026 |
| Feb 19, 2026 | Planned (10b5-1) | Michael E. Prevoznik (SVP & General Counsel) sold 1,111 shares at $204.83 ($228K), marked as a 10b5-1 plan trade. Holdings down 3% to 38,371 shares. | SEC filing Filed Feb 20, 2026 |
| Feb 13, 2026 | Planned (10b5-1) | Catherine T. Doherty (EVP, Regional Businesses) sold 26,165 shares at about $206.15 ($5.4M), marked as a 10b5-1 plan trade. Holdings down 28% to 68,068 shares. | SEC filing Filed Feb 17, 2026 |
| Feb 10, 2026 | Planned (10b5-1) | Patrick Plewman (SVP for Diagnostic Services) sold 5,662 shares at $204.00 ($1.2M), marked as a 10b5-1 plan trade. Holdings down 27% to 15,381 shares. | SEC filing Filed Feb 12, 2026 |
| Nov 25, 2025 | Planned (10b5-1) | J. E. Davis (CEO and Director) sold 55,093 shares at about $192.22 ($10.6M), marked as a 10b5-1 plan trade. Holdings down 31% to 120,480 shares. | SEC filing Filed Nov 28, 2025 |
| Nov 25, 2025 | Sale | Vicky B Gregg (Director) sold 1,250 shares at $191.76 ($240K). Holdings down 7% to 17,037 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 28, 2025 |
| Nov 18, 2025 | Planned (10b5-1) | Mark E. Delaney (SVP & Chief Commercial Officer) sold 7,946 shares at $187.35 ($1.5M), marked as a 10b5-1 plan trade. Holdings down 51% to 7,530 shares. | SEC filing Filed Nov 20, 2025 |
71 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow DGX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.